ReviewMolecular therapy. Nucleic acids2025
The applications of live attenuated influenza a virus with modified NS1 gene.
Review in Molecular therapy. Nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- CRISPR-Cas and Infectious Diseases: A Decade of Translational Advances in Molecular Biotechnology.Biochemical genetics · 2026Review
- Re-engineering segment 8 facilitates generation of a versatile live-attenuated influenza A virus vector platform for secretory protein delivery.Journal of virology · 2026Article
- Chronic Diseases and Influenza Vaccines.Vaccines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, the most effective strategy to prevent influenza is vaccination. While the traditional inactivated influenza vaccine demonstrates favorable safety and effectiveness, live attenuated influenza vaccine (LAIV) offers unique advantages. It has the capability to mimic natural infection through nasal administration and can be quickly prepared in the event of an influenza pandemic. The NS gene, encoding non-structural protein 1 (NS1) and nuclear export protein (NEP), represents the eighth segment of the influenza virus (FluV) genome and plays a crucial role in suppressing host cell interferon production and regulating the nuclear export process of ribonucleoprotein complex during FluV replication. Therefore, the NS gene has gradually become a key target for the development of LAIV in recent years. Manipulating the FluV genome using reverse genetics technology holds promise for enhancing its efficacy and safety as a vaccine vector against respiratory infectious diseases as well as an anti-tumor biological agent. This article provides a comprehensive overview of the research progress in utilizing modified NS FluV as live attenuated vaccines against influenza. Additionally, this review also explores the potential of using FluV with modified NS as vaccine vector for other infectious diseases and as gene therapy tool against tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.